{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:21:37Z","timestamp":1793506897924,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:24:35Z","timestamp":1760073875000},"page":"1592-1597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear-cell Renal Cell Carcinoma: The Multicentre, Single-arm, Phase 2 RENALUT Trial"],"prefix":"10.1016","volume":"8","author":[{"given":"Emmanuel","family":"Seront","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Bsilat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Govaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Liti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedelyn","family":"Cabrieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Dhondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.09.003_b0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.003_b0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.003_b0015","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.003_b0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.003_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.euo.2025.09.003_b0030","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2025.09.003_b0035","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","article-title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.003_b0040","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long\u2010term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.09.003_b0045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.003_b0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.09.003_b0055","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.09.003_b0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2217\/fon-2021-1006","article-title":"CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma","volume":"18","author":"Albiges","year":"2022","journal-title":"Future Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.09.003_b0065","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1200\/JCO.2023.41.6_suppl.606","article-title":"CaboPoint: interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC)","volume":"41","author":"Albiges","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.003_b0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.003_b0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.09.003_b0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0090-4295(00)01094-3","article-title":"Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen","volume":"57","author":"Chang","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.09.003_b0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/cells14030165","article-title":"Vesicles secreted by renal cell carcinoma cells cause vascular endothelial cells to express PSMA and drive tumor progression","volume":"14","author":"Watanabe","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.euo.2025.09.003_b0090","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.juro.2017.08.079","article-title":"Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role","volume":"199","author":"Spatz","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.003_b0095","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12149-015-1017-z","article-title":"Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"29","author":"Rowe","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.euo.2025.09.003_b0100","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12149-019-01371-8","article-title":"Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"33","author":"Meyer","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.euo.2025.09.003_b0105","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.euf.2023.12.004","article-title":"The role of prostate-specific membrane antigen positron emission tomography\/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort","volume":"10","author":"Tariq","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.09.003_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782166","article-title":"Case report: early 68Ga-PSMA-PET metabolic assessment and response to systemic treatment for first-line metastatic clear cell renal cell carcinoma; about two clinical cases","volume":"11","author":"Seront","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2025.09.003_b0115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.euo.2024.02.006","article-title":"A case series study of the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in early evaluation of the response to systemic therapy in metastatic renal cancer","volume":"7","author":"Seront","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.09.003_b0120","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.003_b0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12885-023-11702-8","article-title":"A multicentric, single arm, open-label, phase I\/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)","volume":"24","author":"Kryza","year":"2024","journal-title":"BMC Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500238X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500238X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:42:31Z","timestamp":1778143351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112500238X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S258893112500238X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear-cell Renal Cell Carcinoma: The Multicentre, Single-arm, Phase 2 RENALUT Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}